Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + fulvestrant for secondary endocrine-resistant HR-positive/HER2-negative advanced breast cancer
ChiCTR2100047080Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and fulvestrant in breast cancer, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Started Jun 2021; status: recruiting.
02
Drugs
anlotinibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100047080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047080.